Back to News
Market Impact: 0.2
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist
Source: PR Newswire
Healthcare & BiotechConsumer Demand & Retail
The GLP-1 receptor agonist market is described as experiencing explosive growth amid population aging and expanding weight-management demand. Tirzepatide generated $36.507 billion in annual sales in 2025, underscoring the substantial commercial scale of the obesity and metabolic-disease drug category.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- In photos: China's Xi hardens Taiwan warning as country celebrates week-long National Day holiday
- PHC Holdings surge to near 4-year high after Toho takeover proposal confirmed
- Goldman pushes Fed rate hike to December after cooler inflation
- NIO reports 37,408 vehicle deliveries in September, up 7.7% YoY
- Huawei unveils Mate 90 phones, leans on homegrown chip design to offset US curbs
- US Core PCE Rises 0.2%, Consumer Spending Soars in August
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type